BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Farmers Insurance
Daiichi Sankyo

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022246

« Back to Dashboard

NDA 022246 describes METOZOLV ODT, which is a drug marketed by Salix Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the METOZOLV ODT profile page.

The generic ingredient in METOZOLV ODT is metoclopramide hydrochloride. There are twelve drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.

Summary for 022246

Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 022246

Summary for product number 001

Approval Date:Sep 4, 2009TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Jul 11, 2017Product Flag?YSubstance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Sep 4, 2009TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jul 11, 2017Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 022246

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix PharmsMETOZOLV ODTmetoclopramide hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL022246-001Sep 4, 2009► Subscribe► Subscribe
Salix PharmsMETOZOLV ODTmetoclopramide hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL022246-002Sep 4, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
Fish and Richardson
Johnson and Johnson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: